Artrya vs Cleerly (2026)
Both quantify coronary plaque from CT angiography, but they are bought for different reasons. Artrya's Salix is a reading platform physicians use themselves, starting from an automated analysis they edit before reporting. Cleerly delivers analysis as a service, with plaque quantification (Cleerly Labs, cleared 2020) and an ischemia estimate (Cleerly ISCHEMIA, K231335) validated in the prospective, multicenter CREDENCE trial against invasive FFR. Cleerly documents its reimbursement in detail, with Category I CPT codes and payer coverage, but publishes no price. Artrya is the one of the two with a published contract figure, from an ASX filing. If you want to read and report in house, start with Artrya. If you want an ischemia estimate with a prospective trial behind it, start with Cleerly.
- You want your physicians reading the scan: Salix returns an automated analysis without an external reading team, and the physician edits it before reporting.
- You want to know which outputs are machine learning: the K251837 summary names them and tests them on centers held out from training.
- You want a cost reference before a call: an ASX filing gives US$0.6 million over five years for a five hospital deployment.
- Ischemia is the question: Cleerly ISCHEMIA was validated in CREDENCE, a prospective multicenter trial against invasive FFR with blinded core labs, and K231335 reports its figures with counts.
- You want the security reports without asking: a public trust center offers SOC 2 Type 2 and HITRUST reports for download.
- Reimbursement drives the decision: Category I CPT codes cover plaque analysis and ISCHEMIA, and Cleerly publishes a payer policy lookup tool.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Artrya and Cleerly are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Artrya | Cleerly |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | Not recorded | 2017 |
| Headquarters | Perth, Western Australia, Australia | Denver, Colorado, United States |
| Website | artrya.com | cleerlyhealth.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Artrya, listed on the ASX (AYA) and based in Perth, sells Salix, a cloud platform for reading coronary CT angiography at the point of care. Physicians start from an automated analysis, returned in minutes without an external reading team, and edit it before reporting. Machine learning handles centerline extraction, vessel labeling, lumen and wall segmentation and calcium scoring, and plaque is quantified from Hounsfield unit ranges, including low attenuation plaque, spotty calcification, positive remodeling and the napkin-ring sign.
Source: AI Health Index, September 2026
Cleerly applies AI to coronary CT angiography to quantify and characterize atherosclerotic plaque and estimate ischemia without an invasive test. Cleerly Labs, web based analysis cleared in 2020, measures plaque volume, composition, length and location and stenosis on CCTA from any scanner; Cleerly ISCHEMIA, cleared in 2023 (K231335), estimates vessel level ischemia as a diagnostic aid; Cleerly COMPARE tracks change between scans.
Source: AI Health Index, September 2026
Questions buyers ask
How do Artrya and Cleerly work with the EHR?
Artrya's announcement of its Tanner Health contract says Salix Coronary Anatomy was integrated into Tanner's PACS and electronic medical record and is in clinical use across its five hospitals; Northeast Georgia Health System and Cone Health are further customers. Salix reads DICOM from any CT scanner, and new modules such as Coronary Plaque switch on inside the same interface without a separate integration project.
Cleerly operates as a CCTA analysis service that returns a physician report, sitting in the cardiac imaging and reporting pathway rather than integrating deeply with the EHR. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
How are Artrya and Cleerly priced and sold?
Artrya's ASX announcement of its first US customer states a five year SaaS license for Salix Coronary Anatomy at a monthly subscription fee, valued at US$0.6 million over 60 months for Tanner Health's five hospitals and 30 practices, with a fee per scan added for Coronary Plaque and, once cleared, Coronary Flow. Further US customers are reported on the same subscription plus per scan structure.
Cleerly publishes billing guidelines, coverage pages and a payer policy lookup tool: AI plaque analysis of coronary CT carries Category I CPT code 75577 from January 2026, ISCHEMIA is billable under Category I code 75580, and Medicare contractor and commercial payer policies are reported to cover more than 86 million lives. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Which settings and specialties do Artrya and Cleerly cover?
With Artrya, the cleared indication covers adjunctive analysis of CCTA for patients evaluated for known or suspected coronary disease and calcium scoring on non-contrast cardiac CT, on any CT scanner. The validation in K251837 spans seven US centers, four scanner makers, adults aged 23 to 84 and routine clinician readers.
Cleerly Labs analyzes CCTA from any CT scanner for patients with known or suspected coronary artery disease, and ISCHEMIA estimates vessel level ischemia as a diagnostic aid; COMPARE tracks change between scans. ISCHEMIA was validated in stable patients referred for non-emergent invasive angiography at 23 centers in and outside the US, with results reported for both. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
What evidence is published for Artrya and Cleerly?
For Artrya, the Salix Coronary Plaque 510(k) summary (K251837) reports a retrospective multi-reader study of 103 patients from seven US centers in which routine clinicians using Salix agreed closely with expert readers (stenosis within one CAD-RADS category in 95.8 percent of vessels; total plaque ICC 0.96), which shows the measurements are sound.
With Cleerly, a post-hoc analysis of the PACIFIC trial compared it with FFRCT, PET and SPECT against invasive FFR, and the international CONFIRM2 registry links quantified plaque burden to risk. The company's claims that ISCHEMIA was more accurate than FFRCT and stress testing and was the only non-invasive ischemia test prognostic of later events come from its own analyses of CREDENCE and PACIFIC. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 27, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
CPT codes and payer coverage set what a provider can recover, not what either vendor charges. Cleerly does not publish per study pricing, and Artrya's per scan plaque fee is unpublished. Cleerly COMPARE is marketed without an identified clearance, and Artrya markets Salix for rapid chest pain assessment beyond its adjunctive clearance.